<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710268</url>
  </required_header>
  <id_info>
    <org_study_id>D0810C00022</org_study_id>
    <nct_id>NCT00710268</nct_id>
  </id_info>
  <brief_title>Study to Assess Safety &amp; Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours</brief_title>
  <official_title>A Phase I, Open Label, Dual Centre Study To Assess The Safety And Tolerability Of AZD2281 In Combination With Bevacizumab (AvastinÂ®) In Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I, open label, dual centre, dose finding study to evaluate the safety and tolerability
      of continuous twice daily oral dosing with AZD2281 when administered in combination with
      Bevacizumab 10mg/kg given every 2 weeks to patients with advanced solid tumours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of twice daily oral doses of AZD2281 when administered in combination with Bevacizumab to patients with advanced solid tumours by assessment of adverse events, vital signs, ECG, clinical chem, haematology, urinalysis and phys exam</measure>
    <time_frame>various timepoints.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare exposure to AZD2281 when given alone and in combination with Bevacizumab, by assessment of appropriate derived PK parameters</measure>
    <time_frame>various timepoints.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Study 50, 100, 200, 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2281</intervention_name>
    <description>Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Olaparib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV administration10 mg/kg every 14 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic cancer, not amenable to surgery or radiation
             therapy with curative intent

          -  Adequate bone marrow, kidney and liver function in accordance with laboratory
             parameters set out in the protocol

          -  Estimated life expectancy of at least 12 weeks

        Exclusion Criteria:

          -  Disorders that may put the patient at risk of bleeding, including gastrointestinal
             perforation, intra-abdominal abcess, major surgery of the chest or abdomen, previous
             haemorrhage, coughing up blood or thrombotic event

          -  Hypertension (high blood pressure) or significant cardiovascular disease

          -  Hypersensitivity to Chinese hamster ovary cell products or other recombinant or
             humanised antibodies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Carmichael, BSc MBChB MD FRCP</last_name>
    <role>Study Director</role>
    <affiliation>KuDOS Pharmaceuticals Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcolm Ranson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christie Hospital, Manchester, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1675&amp;filename=D0810C00022.pdf</url>
    <description>D0810C00022_CSR_Synopsis</description>
  </link>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>Poly(ADP ribose) polymerases</keyword>
  <keyword>Metastatic Solid Tumours</keyword>
  <keyword>PARP inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

